# Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment

> **NCT01288131** · PHASE3 · TERMINATED · sponsor: **Chulalongkorn University** · enrollment: 8 (actual)

## Conditions studied

- Anti-r-HuEpo Associated PRCA Subjects

## Interventions

- **DRUG:** Cyclosporine combine with mycophenolate mofetil
- **DRUG:** Cyclophosphamide + pred

## Key facts

- **NCT ID:** NCT01288131
- **Lead sponsor:** Chulalongkorn University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** We observed \>90 % efficacy in cyclophosphamide and Prednisolone group for treatment of anti-i-HuEpo associated PRCA
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288131, "Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01288131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*